Brainstorm Cell Therapeutics | BCLI - Equity Capital And Reserves


Brainstorm Cell Therapeutics reported $-7.69M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Alterity Therapeutics Limited AUD 22.81M 5.29M Jun/2023
Biogen USD 18.21B 573.5M Sep/2025
Brainstorm Cell Therapeutics USD -7.69M 1.64M Sep/2025
Cipla INR 329.19B 16.3B Sep/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 43.83M 6.43M Sep/2025
CSL USD 21.41B 861M Jun/2025
Cytokinetics USD -521.12M 216.32M Sep/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Grifols EUR 6.08B 34.72M Sep/2025
Halozyme Therapeutics USD 503.92M 171.17M Sep/2025
Mesoblast USD 597.44M 136.18M Jun/2025